KR20240022104A - Compositions for muscle strengthening, muscle development or for preventing, ameliorating or treating sarcopenia comprising Boehmeria platanifolia extract as effective component - Google Patents

Abstract

The present invention relates to a composition for strengthening muscle strength, preventing, improving, or treating muscle strength, increasing muscle strength, or decreasing muscle strength, containing an extract of Ga. Mosquito as an active ingredient, wherein the extract of Ga. Mosquito increases the grip strength of an animal model of muscular dystrophy, and the muscle fibers of muscle tissue. Since it has the effect of increasing muscle strength, it can be usefully used as a health functional food, medicine, veterinary product, or feed additive for muscle strengthening, muscle enhancement, muscle differentiation, muscle regeneration, or prevention, improvement, or treatment of muscle loss.

Description

Compositions for muscle strengthening, muscle development or for preventing, ameliorating or treating sarcopenia comprising Boehmeria platanifolia extract as effective component}

The present invention relates to a composition for preventing, improving, or treating muscle strength, muscle gain, or muscle loss, containing an extract of Gamossica as an active ingredient.

The muscles in our body are attached to the bones and perform various functions, such as protecting the bones and maintaining the correct body shape. Additionally, muscles promote calcium influx and increase bone density. However, as the body ages, redistribution of body fat and body protein occurs due to changes in composition, and human muscle gradually decreases after the age of 40, and it is known that 50% of maximum muscle mass is reduced by the age of 80. Muscle loss in old age is recognized as the most important factor that reduces overall physical function, and as aging progresses, changes in body shape, including muscle and fat content and skeletal distortion, are recognized. The prevalence of obesity due to muscle loss in old age is Worldwide, it is showing a continuous increase at more than 30%. In addition, if insulin secretion is abnormal, energy cannot be properly supplied to cells, which can cause muscle development problems, so sarcopenia increases in diabetic patients compared to the general population. Muscle loss causes an increase in arthritis, back pain, and chronic pain, and can also worsen symptoms of urinary incontinence due to abdominal obesity. Injuries due to fractures can increase depression in old age, which can lead to death. The decline not only harms mental health, but is also linked to chronic geriatric diseases and is a major cause of lowering quality of life. Since it is closely related to such geriatric chronic diseases, the decline in physical activity due to aging can be suppressed through the prevention, improvement, or treatment of muscle strength strengthening, muscle enhancement, muscle differentiation, muscle regeneration, or muscle loss.

The global market for treatments for progressive ataxia and muscle weakness recorded approximately $14 billion in 2011, and is expected to grow at a compound annual growth rate of 94% thereafter, reaching approximately $23.5 billion in 2017. Treatments for muscle loss include increasing mitochondrial production, inhibiting muscle protein breakdown, and anti-inflammatory drugs, but there is no clear cure. In addition, the dietary method proposed to prevent sarcopenia in the elderly indicates that 25 to 30 g of high-quality protein should be consumed at each meal. This requires consuming 4-5 eggs or about 120g of chicken breast with each meal, which is difficult for the average person in their daily lives to realistically practice. Therefore, many people have recently chosen protein supplements as an alternative, but protein supplements can cause excessive protein intake and have a high possibility of side effects. Moreover, if you have kidney disease, you cannot eat a high-protein diet, and kidney function also decreases with aging, so alternatives other than high-protein intake are needed to prevent sarcopenia.

On the other hand, it is also called Gamosi, octagonal hemp, Bangma, Yajeoma, Jommosi, and Japanese Mosi. It grows at the foot of mountains and forest edges. It is about 1m high. The stem has blunt ridges and is densely covered with short hairs. The leaves are large, opposite each other, and have long petioles. The leaf shape is round, 10cm long, and 12~l8cm wide. The teeth have deeply grooved edges, and the higher they go, the larger they become, splitting into three at the ends. The upper leaves have short petioles, are egg-shaped, have long, pointed tips, and have short, rough hairs spread out on both sides. The flower is a solitary flower, with light green flowers blooming in water inflorescences from July to August, with male flower spikes at the bottom and female flower spikes at the top. Male flowers have four perianths and stamens, and female flowers ripen surrounded by tube-shaped perianths. The fruit is an achene, round, and grows in clusters. It has wings at the edges and is covered with fur. The leaves are thinner and have larger sawtooths than those of the quince plant, the front is split into three branches, and the flower spikes are thin and long. The young shoots are eaten as a vegetable, and although it is a fibrous plant, the fiber is weak so it is not used very often. In oriental medicine, the leaves and bark are prescribed for diabetes, bleeding, and diuresis. Distributed in Korea (Gyeonggi-do, Hwanghae-do), Japan, and Taiwan.

As for technology related to the quince plant, Korea Patent No. 0947666 discloses a composition and a manufacturing method thereof, and Korean Patent No. 1954190 discloses a pharmaceutical composition for the prevention or treatment of bone disease containing an extract from the genus ginseng. A composition for improving, preventing or treating muscle disease containing a natural product extract is disclosed in Korean Patent No. 1986229, but it has not yet been used to strengthen muscle strength or increase muscle strength containing the extract of Gamosrhiphyllum of the present invention as an active ingredient. Additionally, there has been no disclosure regarding compositions for preventing, improving, or treating muscle loss.

The present invention was developed in response to the above-mentioned needs, and provides a composition for preventing, improving, or treating muscle strength, muscle strength increase, or muscle loss, containing an extract of Ga. Mosquito as an active ingredient, and the extract of Ga. Mosquito is used in an animal model of muscular dystrophy. The present invention was completed by confirming that it has the effect of increasing grip strength and increasing muscle fibers in muscle tissue.

In order to achieve the above object, the present invention provides a health functional food composition for preventing or improving muscle strength, muscle augmentation, muscle differentiation, muscle regeneration, or muscle loss, containing an extract of Gamossica as an active ingredient.

Additionally, the present invention provides a pharmaceutical composition for the prevention or treatment of muscle disease containing an extract of Ga. ginseng as an active ingredient.

Additionally, the present invention provides a veterinary composition for the prevention or treatment of muscle disease containing an extract of Gamossica as an active ingredient.

In addition, the present invention provides a feed additive for preventing or improving muscle strength, muscle augmentation, muscle differentiation, muscle regeneration, or muscle loss, containing the extract of Gamossica as an active ingredient.

The present invention relates to a composition for strengthening muscle strength, preventing, improving, or treating muscle strength, increasing muscle strength, or decreasing muscle strength, containing an extract of Ga. Mosquito as an active ingredient, wherein the extract of Ga. Mosquito increases the grip strength of an animal model of muscular dystrophy, and the muscle fibers of muscle tissue. It has the effect of increasing.

Figure 1 is a schematic diagram of the design of an animal model for muscular dystrophy induced by dexamethasone.
Figure 2 shows the results of confirming the change in body weight following administration of P. orientalis extract to an animal model of muscular dystrophy induced by dexamethasone. Normal is a normal group without any treatment, Control is a control group in which muscle atrophy was induced, OMJ-200 is a positive control group administered Schisandra chinensis extract 200mg/kg/day, and GMS-100 and GMS-200 are 100mg/kg/day. This is an experimental group administered 200mg/kg/day of Gamossica extract.
Figure 3 shows the gastrocnemius (GASTROC), soleus, tibialis anterior (TA), extensor digitorum longus (EDL), and quadriceps muscles according to the administration of P. orientalis extract to a dexamethasone-induced muscular dystrophy animal model. This is the result of checking the weight of the quadriceps (QUAD). * indicates a significant decrease in the weight of the gastrocnemius (GASTROC) and quadriceps (QUAD) muscles in the control group compared to the normal group, p<0.05. # indicates a significant increase in the weight of the gastrocnemius muscle or quadriceps muscle of the Gamossica extract of the present invention and the positive control group compared to the control group, p < 0.05.
Figure 4 shows the results of confirming the grip strength according to the administration of P. orientalis extract to an animal model of muscular dystrophy induced by dexamethasone. *** indicates a statistically significant decrease in the grip strength of the control group compared to the normal group, p < 0.001, and #, ##, ### indicate the grip strength of the group administered the Gapopsis extract of the present invention and the positive control group compared to the control group. A significant increase means # is p<0.05, ## is p<0.01, and ### is p<0.001.
Figure 5 shows the results of H&E staining of a gastrocnemius muscle (GASTROC) tissue section following administration of P. orientalis extract to a dexamethasone-induced muscular dystrophy animal model.
Figure 6 shows the results of confirming the size of muscle fibers of the gastrocnemius muscle according to the administration of the orientalis extract to a dexamethasone-induced muscular dystrophy animal model. * indicates a statistically significant decrease in the size of muscle fibers in the control group compared to the normal group, p<0.05, and # indicates a statistically significant increase in the size of muscle fibers in the group administered the Gamoss extract of the present invention compared to the control group, p<0.05 am.

The present invention relates to a health functional food composition for preventing or improving muscle strength, muscle augmentation, muscle differentiation, muscle regeneration, or muscle loss, containing an extract of Gamossica as an active ingredient.

The Gamossica extract can be prepared by a method comprising the following steps, but is not limited to this:

(1) Extracting by adding an extraction solvent to dried fennel root;

(2) centrifuging the extract of step (1); and

(3) Preparing an extract by drying the centrifuged extract of step (2).

In step (1), the extraction solvent is preferably selected from water, lower alcohols of C ₁ to C ₄ , or mixtures thereof, and more preferably ethanol, but is not limited thereto. In the above manufacturing method, the extraction method can be any conventional method known in the art, such as filtration, hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction. The extraction solvent is preferably added in an amount of 1 to 20 times the weight of the extract, more preferably 5 to 15 times the weight of the extract. The extraction time is preferably 1 to 5 hours, more preferably 1 to 3 hours, and most preferably 2 hours, but is not limited thereto. In step (3), the drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying, or freeze drying, and more preferably freeze drying, but is not limited thereto.

The characteristic feature of the Gamossica extract is that it increases muscle mass or promotes muscle creation.

The health functional food composition is preferably manufactured in a dosage form selected from powder, granule, pill, tablet, capsule, candy, syrup and beverage, but is not limited thereto. The health functional food composition of the present invention can be prepared by adding the extract of Gamossica as is or mixing it with other foods or food ingredients, and can be prepared appropriately according to conventional methods. Examples of foods to which the above-mentioned ginseng extract can be added include caramel, meat, sausages, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, It may be in any form selected from tea, drink, alcoholic beverage, and vitamin complex, and includes all health functional foods in the conventional sense. That is, there are no particular restrictions on the type of food. The health functional food composition includes various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, and protective colloidal thickeners. , pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. Additionally, it may contain pulp for the production of natural fruit juice and vegetable drinks. The above components can be used independently or in combination. In addition, the health functional food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients, and the natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, dextrins, and cyclosaccharides. These are polysaccharides such as dextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. The ratio of the natural carbohydrate is not very important, but is preferably 0.01 to 0.04 g, more preferably 0.02 to 0.03 g, per 100 g of the composition of the present invention, but is not limited thereto. As sweeteners, natural sweeteners such as thaumatin and stevia extract, and synthetic sweeteners such as saccharin and aspartame can be used.

In addition, the present invention relates to a pharmaceutical composition for the prevention or treatment of muscle disease containing an extract of Ga. ginseng as an active ingredient.

The muscle disease is a muscle disease caused by decreased muscle function, muscle atrophy, muscle wasting, or muscle degeneration, and is more preferably atony, muscular atrophy, muscular dystrophy, myasthenia gravis, and cachexia ( cachexia, rigid spine syndrome, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, and sarcopenia. However, it is not limited to this.

Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are those commonly used in preparation, and include saline solution, sterile water, Ringer's solution, buffered saline solution, dextrose solution, maltodextrin solution, glycerol, ethanol, lactose, and water. Cloth, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate. Includes, but is not limited to, nitrite, talc, magnesium stearate, and mineral oil. In addition to the above ingredients, it may further include antioxidants, buffers, bacteriostatic agents, diluents, surfactants, binders, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, or preservatives. The appropriate dosage of the pharmaceutical composition of the present invention may be prescribed in various ways depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity. You can. The administration route of the pharmaceutical composition for preventing or treating muscle diseases of the present invention may be administered through any generally accepted route as long as it can reach the target tissue. The pharmaceutical composition of the present invention is not particularly limited thereto, but depending on the purpose, intramuscular administration, eye drop administration, intraperitoneal administration, intravenous administration, subcutaneous administration, intradermal administration, transdermal patch administration, oral administration, intranasal administration, intrapulmonary administration, It may be administered through routes such as intrarectal administration, and specifically, may be administered through intramuscular administration.

Additionally, the present invention relates to a veterinary composition for the prevention or treatment of muscle disease containing an extract of Ga. ginseng as an active ingredient.

The veterinary composition of the present invention may further include appropriate excipients and diluents according to conventional methods. Excipients and diluents that may be included in the veterinary composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxy benzoate, propyl hydroxy benzoate, talc, magnesium stearate, cetanol, stearyl alcohol, liquid paraffin, sorbitan monostearate. , polysorbate 60, methylparaben, propylparaben, and mineral oil. The veterinary composition according to the present invention may further include fillers, anti-aggregants, lubricants, wetting agents, spices, emulsifiers, preservatives, etc. The veterinary composition according to the present invention provides rapid and sustained release of the active ingredient after administration to an animal. or may be formulated using methods well known in the art to provide sustained release, the dosage form being powders, granules, tablets, capsules, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, It may be in the form of a suppository, sterile injectable solution, or sterile topical medication.

The effective amount of the veterinary composition according to the present invention can be appropriately selected depending on the individual animal. Severity of the disease or condition, sensitivity to the active ingredient of the present invention depending on the individual's age, weight, health condition or gender, administration route, administration period, factors including other compositions mixed or used simultaneously with the composition, and other physiological or It can be determined based on factors well known in the veterinary field.

In addition, the present invention relates to a feed additive for preventing or improving muscle strength, muscle augmentation, muscle differentiation, muscle regeneration, or muscle loss, containing an extract of Gamossica as an active ingredient.

The feed additive of the present invention corresponds to supplementary feed under the Feed Management Act. In the present invention, the term 'feed' may mean any natural or artificial diet, meal, etc., or a component of the meal, for or suitable for eating, ingestion, and digestion by animals. The type of feed is not particularly limited, and feed commonly used in the art can be used. Non-limiting examples of the feed include plant feeds such as grains, roots and fruits, food processing by-products, algae, fiber, pharmaceutical by-products, oils and fats, starches, cucurbits or grain by-products; Examples include animal feeds such as proteins, inorganic substances, fats and oils, minerals, oils and fats, single-cell proteins, zooplanktons or food. These may be used alone or in combination of two or more types.

Hereinafter, the present invention will be described in more detail using examples. These examples are only for illustrating the present invention in more detail, and it is obvious to those skilled in the art that the scope of the present invention is not limited thereto.

Example 1. Extract preparation

Dried Achyranthes leaves were refluxed and extracted twice with 10 times 70% ethanol for 2 hours each, filtered, and the filtrate was concentrated under reduced pressure and then freeze-dried.

Example 2. Effect of improving muscle loss in a dexamethasone-induced muscle atrophy animal model

(1) Design of experimental animals and muscular dystrophy animal models

In order to conduct animal testing, approval was obtained from the Animal Experiment Ethics Committee of the Korea Institute of Oriental Medicine, and all animal testing procedures were conducted in compliance with the ethical procedures for animal testing. The experimental animals used were 7-week-old male C57BL/6 mice weighing 21 to 23 g purchased from Central Laboratory Animals. Experimental animals were used in experiments after acclimatizing for one week in an environment of 23 ± 2°C, relative humidity of 55 ± 10%, illuminance of 150 to 300 lux, and light/dark cycle at 12-hour intervals. The experimental animals were untreated group (Normal), dexamethasone treated group (Control), dexamethasone + gaemosipul (GMS) extract 100mg/kg (GMS-100), dexamethasone + gaemosipul (GMS) extract 200mg/kg (GMS-200), Dexamethasone + Schisandra chinensis extract 200mg/kg (OMJ-200) was divided into 8 animals each, randomly classified.

The animal model in which muscular dystrophy was induced was designed as shown in Figure 1. Excluding the normal group, mice were intraperitoneally injected with dexamethasone at a dose of 20 mg/kg/day for 12 days. The P. syringa extract was administered orally for 19 days using a sonde starting 7 days before intraperitoneal administration of dexamethasone at doses of 100 mg/kg/day and 200 mg/kg/day, respectively. During the same period, the positive control group, Schisandra chinensis extract, was orally administered at a dose of 200 mg/kg/day, and the normal group was orally administered the same volume of saline solution.

(2) Weight measurement

Body weight was measured before drug administration and on the 3rd and 7th days after dexamethasone administration.

As a result, as shown in Figure 2, there was no significant difference in body weight change in all four groups during the adaptation period of the experimental animals. The Control group showed a significant decrease in body weight compared to the Normal group from 3 to 7 days after dexamethasone administration. Similarly, the group administered the Gamosrhiphyllum extract of the present invention (GMS-100, GMS-200) and the Schisandra chinensis extract administered group (OMJ-200), which is a positive control group, showed a decrease in body weight due to dexamethasone administration compared to the Normal group, like the control group. . No significant difference in body weight change was observed between the control group and the extract administration group.

(3) Measurement of muscle wet weight

The control and experimental groups were euthanized at the end of the experiment, and the gastrocnemius (GASTROC), soleus, tibialis anterior (TA), extensor digitorum longus (EDL), and quadriceps (QUAD) muscles were separated. The wet weight of the muscle was measured.

As a result, as shown in Figure 3, there was no significant difference in the weight of the soleus, tibialis anterior (TA), and extensor digitorum longus (EDL) of the control group and the extract administration group compared to the normal group. The weight of the gastrocnemius muscle (GASTROC) and quadriceps femoris muscle (QUAD) in one control group was statistically significantly reduced. In contrast, the weight of the gastrocnemius muscle or quadriceps muscle of the group administered the Gamossica extract of the present invention (GMS-200) or the group administered the Schisandra chinensis extract (OMJ-200), which is a positive control group, significantly increased.

(4) Measurement of grip strength

At the end of the experiment, a grip strength test was conducted to measure grip strength. Grip strength was measured using a Grip Strength Meter (47200UB; Ugo Basile, Gemonio, Italy). The animal model in each group was allowed to hold the tail and hold the bar of the device, and the maximum force presented when the tail was pulled horizontally at a constant speed (2 cm/sec) until the grip of the mouse in each group was released was measured. (grip strength). Five measurements were obtained for each mouse and the average value was calculated.

As a result, as shown in Figure 4, in the grip strength test performed on the same mouse, the grip strength of the control group administered dexamethasone was 129.7 ± 9.1 gf, which was decreased compared to 164.3 ± 14.6 gf of the normal group. On the other hand, grip strength in the GMS-100 and GMS-200 groups increased significantly compared to the control group, reaching 147.2 ± 11.6 gf and 156.1 ± 7.0 gf, respectively, and in the positive control group, OMJ-200 group, it also increased to 141.9 ± 12 gf. increased compared to . From these results, it was determined that the Gamossica extract could more effectively restore the decrease in muscle function in the muscle atrophy model induced by dexamethasone compared to the Schisandra chinensis extract.

(5) H&E staining of muscle tissue and measurement of muscle fiber area

After completion of the experiment, the gastrocnemius muscle of the muscular dystrophy animal model was isolated, fixed in 10% formalin, and embedded in paraffin. The prepared paraffin blocks were sectioned to a thickness of 5 μm to make slides, and hematoxylin and eosin (H&E) staining was performed. The stained tissue was randomly photographed in 3 areas at 400 , CSA) was measured.

As a result, as shown in Figures 5 and 6, the size of muscle fibers confirmed by H&E staining of gastrocnemius muscle tissue in the same mouse model was significantly higher in the control group administered dexamethasone (1637.2±157.5μm²) compared to the normal group (1925±222.98μm²). decreased. On the other hand, the muscle fiber size of the GMS-200 group was found to be 1880.8±190.8μm², indicating a significant increase.

Meanwhile, the OMJ-200 group was observed to have a lower size compared to the Control group at 1348.3±255μm².

From these results, it was found that the administration of the Extract of Echinacea inhibits muscle atrophy caused by dexamethasone, and the Efficacy of the Extract of the Extract was shown to be similar or better than that of Schisandra chinensis extract administered at the same dose.

Claims (8)

A health functional food composition for preventing or improving muscle strength, muscle enhancement, muscle differentiation, muscle regeneration, or muscle loss, containing Boehmeria platanifolia extract as an active ingredient. The method of claim 1, wherein the extraction solvent of the Gamossica extract is one selected from water, lower alcohols of C ₁ to C ₄ , and mixtures thereof for muscle strength strengthening, muscle enhancement, muscle differentiation, muscle regeneration or muscle strength. Health functional food composition for preventing or improving reduction. The health functional food for preventing or improving muscle strength, muscle augmentation, muscle differentiation, muscle regeneration, or muscle loss according to claim 1, wherein the extract is an increase in muscle mass or promotes muscle production. Composition. A pharmaceutical composition for the prevention or treatment of muscle disease containing an extract of Gamossica as an active ingredient. The pharmaceutical composition for preventing or treating muscle diseases according to claim 4, wherein the muscle disease is a muscle disease caused by decreased muscle function, muscle atrophy, muscle wasting, or muscle degeneration. The method of claim 5, wherein the muscle disease is atony, muscular atrophy, muscular dystrophy, myasthenia gravis, cachexia, rigid spine syndrome, and amyotrophic lateral sclerosis. A pharmaceutical composition for the prevention or treatment of muscle disease, characterized in that it is at least one selected from the group consisting of lateral sclerosis, Charcot-Marie-Tooth disease, and sarcopenia. A veterinary composition for the prevention or treatment of muscle disease containing an extract of Gamossica as an active ingredient. A feed additive for muscle strength strengthening, muscle augmentation, muscle differentiation, muscle regeneration, or prevention or improvement of muscle loss containing extract of Gamosrhifolia as an active ingredient.